UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2317-2
Program Prior Authorization/Medical Necessity
Medication Litfulo™ (ritlecitinib)
P&T Approval Date 11/2023, 12/2024
Effective Date 3/1/2025
1. Background:
Litfulo (ritlecitinib) is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults
and adolescents 12 years and older.
Limitations of Use:
Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators,
cyclosporine or other potent immunosuppressants
2. Coverage Criteriaa:
A. Initial Authorization
1. Litfulo will be approved based on all of the following criteria:
a. Diagnosis of severe alopecia areata
-AND-
b. Other causes of hair loss have been ruled out (e.g., androgenetic alopecia, cicatricial
alopecias, secondary syphilis, tinea capitis, triangular alopecia, and trichotillomania)
-AND-
c. Patient has a current episode of alopecia areata with at least 50% scalp hair loss
-AND-
d. Patient is not receiving Litfulo in combination with either of the following:
(1) Targeted immunomodulator [e.g., Olumiant (baricitinib), Enbrel (etanercept),
Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
(2) Potent immunosuppressant (e.g., azathioprine or cyclosporine)
-AND-
e. Prescribed by or in consultation with a dermatologist
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services Inc.
1
B. Reauthorization
1. Litfulo will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Litfulo therapy
-AND-
b. Patient is not receiving Litfulo in combination with either of the following:
(1) Targeted immunomodulator [e.g., Olumiant (baricitinib), Enbrel (etanercept),
Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
(2) Potent immunosuppressant (e.g., azathioprine or cyclosporine)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
4. References:
1. Litfulo [package insert]. New York, NY: Pfizer, Inc.; June 2023.
2. Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists' guidelines for
the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916-926.
3. King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for
clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol.
2022;86(2):359-364.
4. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: Results
of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol.
2020;83(1):123-130.
5. King BA, Senna MM, Ohyama M, et al. Defining Severity in Alopecia Areata: Current
Perspectives and a Multidimensional Framework. Dermatol Ther (Heidelb). 2022 Apr;12(4):825-
834.
Program Prior Authorization/Medical Necessity - Litfulo (ritlecitinib)
Change Control
11/2023 New program.
12/2024 Annual review with no change to coverage criteria.
© 2024 UnitedHealthcare Services Inc.
2